Defiance ETFs’s Bristol-Myers Squibb BMY Stock Holding History

Defiance ETFs’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$485K	Buy	8,698 +1,972	+29%	+$113K	0.01%	282
2026 Q1	$408K	Buy	+6,726	New	+$392K	0.01%	277

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Defiance ETFs's BMY Position: Q2 2026 in Review

Defiance ETFs increased its Bristol-Myers Squibb (BMY) stake by 29% in Q2 2026, buying an estimated $113K and bringing the position to 8,698 shares worth $485K. The position accounts for 0.01% of the portfolio, ranked #282.

Defiance ETFs first reported a position in BMY in Q1 2026 and has held it in 2 quarters since. 2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Defiance ETFs held 8,698 shares of Bristol-Myers Squibb worth $485K as of Q2 2026.
Defiance ETFs bought 1,972 Bristol-Myers Squibb shares in Q2 2026, an estimated $113K.
Bristol-Myers Squibb made up 0.01% of Defiance ETFs's portfolio in Q2 2026, its #282 holding.
Defiance ETFs first reported a position in Bristol-Myers Squibb in Q1 2026 and has held it in 2 quarters since.
2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Defiance ETFs's 13F filing for Q2 2026, filed 14 Aug 2026.